查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138297

2022-2029 年全球甲型肝炎疫苗市場

Global Hepatitis A Vaccine Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 190 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

政府加大預防力度

甲型肝炎疫苗用於阻止不斷上升的甲型肝炎病例。根據美國疾病控制與預防中心的數據，2018 年美國共報告了 12,474 例甲型肝炎病例，加上未確診病例，該機構估計年度報告的實際數量為 24,900 例。這就是為什麼政府正在加緊努力提高認識、診斷、治療和接種疫苗。截至 2022 年 4 月 21 日，世衛組織歐洲區域的 11 個國家和世衛組織美洲區域的 1 個國家報告了至少 169 例原因不明的急性肝炎病例。據世界衛生組織稱，在衛生和個人衛生習慣不足的發達國家，大約 90.0% 的兒童在 10 歲時感染了甲型肝炎病毒。政府的疫苗接種計劃正在推動發展中國家甲型肝炎疫苗的全球市場。

另一方面，缺乏個人對甲型肝炎的認識預計將成為預測期內抑制全球市場增長的主要因素。此外，居民對診斷的抵制也阻礙了市場的增長。

本報告提供了大約 48 個市場數據表、43 個圖表和 190 頁有關全球甲型肝炎疫苗市場的信息。

內容

第一章調查方法及範圍

  • 調查方法
  • 市場範圍

第 2 章主要趨勢和發展

第 3 章執行摘要

  • 按產品類型劃分的市場細分
  • 按應用劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
    • 約束因素
    • 商機
  • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • PEST 分析
  • 定價分析
  • 報銷分析
  • 監管分析
  • 未滿足的需求
  • 專利趨勢

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措

第 7 章按產品類型

  • 滅活□□疫苗
  • 減毒活疫苗

第 8 章按應用程序

  • 政府機構
  • 私營公司
  • 其他

第 9 章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章競爭格局

  • 競爭場景
  • 競爭對手戰略分析
  • 市場情況/份額分析
  • 併購分析

第 11 章公司簡介

  • GlaxoSmithKline
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Merck & Co., Inc.
  • Sanofi
  • Sinovac
  • Zhejiang Pukang
  • Changchun Institute of Biological
  • KM Biologics
  • IMBCA
  • ChangSheng
  • Convac

第12章 DataM

簡介目錄
Product Code: DMPH3111

Market Overview

Hepatitis A Vaccine Market size was valued at USD 876.9 million in 2021 and is estimated to reach at a compound annual growth rate (CAGR) of 3.5% over the forecast period 2022 to 2029.

Hepatitis A vaccine is a vaccine that prevents hepatitis A. The disease is a liver disorder caused by the hepatitis A virus leading from mild to severe illness. The Hepatitis A Virus (HAV) is transferred through either ingestion of contaminated food and water or direct contact with an infectious person. The disease has a propensity for cyclic reappearances, which occurs in epidemics globally. The antibodies introduced in response to the disease lasts through life and protect against recurrence of infection, the best way for which is through vaccination. It is given in two doses injected six months apart. The major factors propelling the growth of the Hepatitis A vaccine market are the increasing prevalence of hepatitis A globally, which leads to increasing concerns for vaccination. The rise in the number of Hepatitis A cases propels the national governments and healthcare organizations to introduce steps to increase awareness about the disease and manage vaccination drives in the risk-prone areas. Further continuous efforts by the market players to promote Hepatitis A vaccines drive the market growth.

Market Dynamics: Increasing government initiatives for prevention

Hepatitis A Vaccine is used to submerge the rising cases of Hepatitis A. As per the Center for Disease Control, in 2018, the U.S. reported a total of 12,474 hepatitis A cases, and the organization estimated the actual number of cases reported in the year to be 24,900 owing to the undiagnosed cases. This has propelled governments to increase their efforts for awareness, diagnosis, treatment, and vaccination. As of 21 April 2022, at least 169 cases of acute hepatitis of unknown origin have been reported from 11 countries in the WHO European Region and one country in the WHO Region of the Americas. According to the WHO, approximately 90.0% of children are infected with the hepatitis A virus before 10 years in developed countries with inadequate sanitary conditions and sanitation habits. Government vaccination programs are propelling the worldwide market for hepatitis A vaccines in developing countries.

On the other hand, lack of awareness concerning the Hepatitis A disease among individuals is a key factor expected to curtail the global market's growth over the forecast period. Moreover, resistance among the population for diagnosis also obstructs market growth.

Market Segmentation: Inactivated vaccine segment is projected to be the dominant segment in the market during the forecast period

Inactivated vaccines dominated the global market in 2019, also it is expected to present considerable growth shortly. Inactivated Vaccines are safe and highly functional. A two-dose schedule is traditionally recommended, particularly for travelers at significant risk of contracting hepatitis A and immunocompromised individuals. However, with a single dosage, equivalent efficacy has been achieved in stable people. This is expected to propel segmental growth soon.

Based on application, government institutions held the dominant position in the global market during the forecast period. Patients depend on public healthcare facilities for diagnosis and proper vaccination of Hepatitis A, supporting the segment growth during the forecast period. Moreover, the surging government programs offering vaccination drives are expected to project a considerable CAGR during the forecast period.

Geographical Penetration: Asia-Pacific is expected to dominate the global Hepatitis A Vaccine market

Asia-Pacific held a dominant position in the global Hepatitis A Vaccine market in 2021. In Asia-Pacific, China is expected to represent considerable growth during the forecast period. As in China, the live attenuated Hepatitis A Vaccine is becoming a favorable element to tackle the disease. Moreover, Europe is expected to represent significant growth in terms of value during the forecast period. The easy availability of vaccines at a comparatively lower cost is expected to propel market growth across the region. The Hepatitis A Vaccine market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by government policies and programs, especially in India and China. Moreover, the rise in the pediatric population and increased awareness about vaccination results in increasing demand for Hepatitis A Vaccine in emerging economies, such as India and China, which is expected to augment Asia Pacific's growth Hepatitis A Vaccine market.

Competitive Landscape:

The Hepatitis A Vaccine market is highly competitive, owing to the presence of major market players. The key Hepatitis A Vaccine player contributing to the global market's growth include GlaxoSmithKline, Merck & Co. Inc., Sanofi, Sinovac, Zhejiang Pukang, Changchun Institute of Biological, KM Biologics, IMBCA, ChangSheng, Convac, among others. The major players are adopting new expansion strategies for global growth in the Hepatitis A Vaccine market.

COVID-19 Impact: Negative impact on the global Hepatitis A Vaccine market

The outbreak of COVID-19 has negatively impacted the growth of the Hepatitis A Vaccine market globally. The disruption in the supply chain has majorly impacted the growth of the market amidst the pandemic. The escalated focus on COVID-19 vaccine development, product type, and distribution has led to de-escalation in Hepatitis A vaccines. Therefore, the COVID-19 pandemic has hampered the market value of the Hepatitis A Vaccine market in 2021

The global Hepatitis A Vaccine market report would provide an access to approximately 48 market data tables, 43 figures and 190 pages

Table of Contents

Scope and Methodology

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Supply Chain analysis
  • 5.3. PEST Analysis
  • 5.4. Pricing Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Unmet Needs
  • 5.8. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Product Type Segment
    • 7.1.2. Market attractiveness index, By Product Type Segment
  • 7.2. Inactivated Vaccine*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Live Attenuated Vaccine

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Application Segment
    • 8.1.2. Market attractiveness index, By Application Segment
  • 8.2. Government Institution *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Private Sector
  • 8.4. Other

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key region-specific dynamics
    • 9.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Rest of South America
  • 9.4. Europe
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.4.5.1. Germany
      • 9.4.5.2. U.K.
      • 9.4.5.3. France
      • 9.4.5.4. Spain
      • 9.4.5.5. Italy
      • 9.4.5.6. Rest of Europe
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

10. Competitive Landscape

  • 10.1. Competitive scenario
  • 10.2. Competitor strategy analysis
  • 10.3. Market positioning/share analysis
  • 10.4. Mergers and acquisitions analysis

11. Company Profiles

  • 11.1. GlaxoSmithKline *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Merck & Co., Inc.
  • 11.3. Sanofi
  • 11.4. Sinovac
  • 11.5. Zhejiang Pukang
  • 11.6. Changchun Institute of Biological
  • 11.7. KM Biologics
  • 11.8. IMBCA
  • 11.9. ChangSheng
  • 11.10. Convac
  • List not Exhaustive*

12. DataM

  • 12.1. Appendix
  • 12.2. About us and services
  • 12.3. Contact us